<abstract xmlns="http://www.w3.org/1999/xhtml"><sec id="j_fco-2019-0023_s_005_w2aab3b7c12b1b6b1aab1c15b1Aa"><h3>Background</h3><p>Desmoid tumors/aggressive fibromatosis (DTs/AF) are cytological bland fibrous neoplasms originating from the musculoaponeurotic structures throughout the body. The exact cause still remains unknown, however, they may present sporadically or as a manifestation of a hereditary syndrome called familial adenomatous polyposis <italic>(FAP</italic>). Although they lack the capacity to establish metastases, DTs/AF may be devastated and occasionally fatal. As a result of the heterogeneity of DTs/AF, treatment needs to be individualized to improve local tumor control and maintain patients’ quality of life. Therefore, after a multidisciplinary approach, all treatment options should be discussed with patients. Where systemic chemotherapy has been shown to be unsuccessful with marked side effects in case of advanced DTs/AF, new therapeutic options are needed.</p></sec><sec id="j_fco-2019-0023_s_006_w2aab3b7c12b1b6b1aab1c15b2Aa"><h3>Methods</h3><p>A Medline search was conducted and published articles in different studies from 2000 to the present were reviewed.</p></sec><sec id="j_fco-2019-0023_s_007_w2aab3b7c12b1b6b1aab1c15b3Aa"><h3>Conclusion</h3><p>More research is needed to illustrate both the prognostic and predictive factors of the targeted therapy and the value of their combinations with or without other treatment modalities to get the best result for the treatment of advanced DTs/AF.</p></sec></abstract>

BackgroundDesmoid tumors/aggressive fibromatosis (DTs/AF) are cytological bland fibrous neoplasms originating from the musculoaponeurotic structures throughout the body. The exact cause still remains unknown, however, they may present sporadically or as a manifestation of a hereditary syndrome called familial adenomatous polyposis (FAP). Although they lack the capacity to establish metastases, DTs/AF may be devastated and occasionally fatal. As a result of the heterogeneity of DTs/AF, treatment needs to be individualized to improve local tumor control and maintain patients’ quality of life. Therefore, after a multidisciplinary approach, all treatment options should be discussed with patients. Where systemic chemotherapy has been shown to be unsuccessful with marked side effects in case of advanced DTs/AF, new therapeutic options are needed.MethodsA Medline search was conducted and published articles in different studies from 2000 to the present were reviewed.ConclusionMore research is needed to illustrate both the prognostic and predictive factors of the targeted therapy and the value of their combinations with or without other treatment modalities to get the best result for the treatment of advanced DTs/AF.

Targeted therapy in advanced desmoid tumors: Current perspectives

Forum of Clinical Oncology

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

{"article-title":"Targeted therapy in advanced desmoid tumors: Current perspectives"}

BackgroundDesmoid tumors/aggressive fibromatosis (DTs/AF) are cytological bland fibrous neoplasms originating from the musculoaponeurotic structures throughout...

Targeted therapy in advanced desmoid tumors: Current perspectives

Article Category: Research Article

Publicado en línea: 22 abr 2021

Páginas: 9 - 16

Recibido: 21 nov 2020

Aceptado: 11 dic 2020

DOI: https://doi.org/10.2478/fco-2019-0023

Palabras clave
Desmoid tumors, aggressive fibromatosis, targeted therapy, molecular pathogenesis

© 2020 Amrallah A. Mohammed, Hani EL-Tanni, Hani M. EL-Khatib, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Targeted therapy in advanced desmoid tumors: Current perspectives

Article Category: Research Article

Publicado en línea: 22 abr 2021

Páginas: 9 - 16

Recibido: 21 nov 2020

Aceptado: 11 dic 2020

DOI: https://doi.org/10.2478/fco-2019-0023

Palabras claveDesmoid tumors, aggressive fibromatosis, targeted therapy, molecular pathogenesis

© 2020 Amrallah A. Mohammed, Hani EL-Tanni, Hani M. EL-Khatib, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Palabras clave
Desmoid tumors, aggressive fibromatosis, targeted therapy, molecular pathogenesis